NCT03531632View on ClinicalTrials.gov

MGD007 Combined With MGA012 in Relapsed/Refractory Metastatic Colorectal Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

June 4, 2018

Primary Completion Date

February 8, 2020

Study Completion Date

February 8, 2020

Conditions
Colorectal Cancer Metastatic
Interventions
BIOLOGICAL

MGD007 + MGA012

MGD007 and MGA012 are administered by IV infusion.

Trial Locations (6)

14642

University of Rochester Medical Center, Rochester

28078

Carolina Biooncology Institute, Huntersville

33612

Moffitt Cancer Center, Tampa

98109

University of Washington, Seattle

06520

Yale School of Medicine, New Haven

02114

Massachusetts General Hospital, Boston

Sponsors

Lead Sponsor

MacroGenics
All Listed Sponsors
lead

MacroGenics

INDUSTRY